Soluble CD40 ligand and atrial fibrillation: Relationship to platelet activation, and endothelial damage/dysfunction

International Journal of Cardiology

Volumn 127, Issue 1, 2008, Pages 135-137

  Blann, A D ^a   Choudhury, A ^a   Freestone, B ^a   Patel, J ^a   Lip, G Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Soluble CD40 ligand

Indexed keywords

CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD40 LIGAND; CHI-SQUARE DISTRIBUTION; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; STATISTICS, NONPARAMETRIC;

EID: 43949144187     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.04.028     Document Type: Article

References (19)

1. Wattigney W.A., Mensah G.A., and Croft J.B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108 (2003) 711-716
2. Conway D.S.G., Pearce L.A., Chin B.S.P., et al. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with non-valvular atrial fibrillation: relationship to stroke risk factors. Circulation 106 (2002) 1962-1967
3. Anand S.X., Viles-Gonzalez J.F., Badimon J.J., Cavusoglu E., and Marmur J.D. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 90 (2003) 377-384
4. Heeschen C., Dimmeler S., Hamm C.W., et al. For the Capture Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
5. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
6. Weber A.A., Hermann A., and Rauch B.H. Molecular identity of platelet CD40 ligand (CD40L). Thromb Haemost 86 (2001) 718
7. Machin D., and Campbell M. Statistical Tables for the Design of Clinical Trials (1987), Blackwell Scientific, Oxford
8. Stumpf C., Lehner C., Eskafi S., et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 5 (2003) 629-637
9. Otterdal K., Pedersen T.M., and Solum N.O. Release of soluble CD40 ligand after platelet activation; studies on the solubilization phase. Thromb Res 114 (2004) 167-177
10. Ahn E.R., Lander G., Jy W., et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114 (2004) 143-148
11. Furman M.I., Krueger L.A., Linden M.D., Barnard M.R., Frelinger III A.L., and Michelson A.D. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 16 43 (2004) 2319-2325
12. Andre P., Prasad K.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a beta3 integrin dependent mechanism. Nat Med 8 (2002) 247-252
13. Nannizzi-Alaimo L., Alves V.L., Phillips D.R., et al. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107 (2003) 1123-1128
14. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
15. Blann A.D., Nadar S.K., and Lip G.Y.H. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 24 (2003) 2166-2179
16. Blann A.D. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 95 (2006) 49-55
17. Damas J.K., Otterdal K., Yndestad A., et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 110 (2004) 999-1005
18. Patel J., Lim H.S., Nadar S., Tayebjee M., Hughes E., and Lip G.Y.H. Abnormal soluble CD40 ligand and C-reactive protein levels in hypertension: relationship to indices of angiogenesis. J Hypertens 24 (2006) 117-121
19. Ueland T., Aukrust P., Yndestad A., et al. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 26 (2005) 1101-1107